Nathan Bittner, MD, MS | Authors

Articles

Interstitial Brachytherapy Should Be Standard of Care for Treatment of High-Risk Prostate Cancer

August 01, 2008

Given the poor outcomes observed with radical prostatectomy (RP) and external-beam radiation therapy (EBRT), some in the urologic community contend that high-risk disease is not curable with currently available treatment strategies.[1,2] In fact, there is a growing contingent of clinicians who advocate the use of chemotherapy in conjunction with RP. With the established efficacy of brachytherapy, these efforts are likely excessive.